The Health Effect Of Psychostimulants: A Literature Review

Pharmaceuticals

Volumn 3, Issue 7, 2010, Pages 2333-2361

  Favrod Coune, Thierry ^a   Broers, Barbara ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Amphetamines; Cocaine; Ecstasy (MDMA); Khat; Nicotine; caffeine; Psychostimulants

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CATHA EDULIS EXTRACT; CITALOPRAM; COCAINE; FLUOXETINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NICOTINE; ONDANSETRON; PSYCHOSTIMULANT AGENT; TIAGABINE; TOPIRAMATE; VARENICLINE;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CARDIOTOXICITY; CIGARETTE SMOKING; CLINICAL TRIAL; COCAINE DEPENDENCE; CULTURAL FACTOR; DAYTIME SOMNOLENCE; DIETARY INTAKE; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; HEALTH HAZARD; HUMAN; HYPERSOMNIA; NARCOLEPSY; NEUROTOXICITY; NONHUMAN; OBESITY; PSYCHOSOCIAL CARE; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SLEEP DISORDER; SUBSTANCE ABUSE; THERAPY EFFECT; TOBACCO DEPENDENCE; WEIGHT CONTROL; WITHDRAWAL SYNDROME;

EID: 77955675576     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3072333     Document Type: Review

References (200)

1. Flegal, K.M.; Carroll, M.D.; Ogden, C.L.; Johnson, C.L. Prevalence and trends in obesity among US adults, 1999-2000.JAMA 2002, 288, 1723-1727.
2. Froehlich, T.E.; Lanphear, B.P.; Epstein, J.N.; Barbaresi, W.J.; Katusic, S.K.; Kahn, R.S. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch. Pediatr. Adolesc. Med. 2007, 161, 857-864.
3. Kessler, R.C.; Adler, L.; Barkley, R.; Biederman, J.; Conners, C.K.; Demler, O.; Faraone, S.V. Greenhill, L.L.; Howes, M.J.; Secnik, K.; et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am. J. Psychiatry 2006, 163, 716-723.
4. Longstreth, W.T., Jr; Koepsell, T.D.; Ton, T.G.; Hendrickson, A.F.; van Belle, G. The epidemiology of narcolepsy. Sleep 2007, 30, 13-26.
5. Knorr, U.; Kessing, L.V. The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review. Nord. J. Psychiatry 2010, 64, 153-163.
6. WHO Report on the Global Tobacco Epidemic, 2008-The MPOWER package, http://www.who.int/tobacco/mpower/en/index.html/ accessed on 22 July 2010.
7. Observatoire européen des drogues et des toxicomanies. Rapport annuel 2009 - État du phénomène de la drogue en Europe; Luxembourg: Office des publications de l'Union européenne, Lisbon, Portugal, 2009.
8. Proceedings of the Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse. Advance Report and Highlights/Executive Summary: Abuse of Stimulants and Other Drugs; U.S. Department of Health and Human Services, National Institutes of Health: Bethesda, Maryland, USA, 2005; http://www.drugabuse.gov/PDF/CEWG/AdvReport_Vol1_105.pdf/, accessed on 21 July 2010.
9. Degenhardt, L.; Chiu, W.-T.; Sampson, N.; Kessler, R.C.; Anthony, J.C.; Angermeyer, M.; Bruffaerts, R.; de Girolamo, G.; Gureje, O.; Huang, Y.; et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health Surveys. PLoS Med. 2008, 5, e141.
10. Pinto, E.; Pitchot, W.; Ansseau, M. Pychostimulants. Rev Med Liege 2008, 63, 411-416.
11. Corti, R.; Binggeli, C.; Sudano, I.; Spieker, L.; Hänseler, E.; Ruschitzka, F.; Chaplin, WF.; Lüscher, T.F.; Noll, G. Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content: role of habitual versus nonhabitual drinking. Circulation 2002, 106, 2935-2940.
12. Harland, B.F. Caffeine and nutrition. Nutrition 2000, 16, 522-526.
13. Grigg, D. The worlds of tea and coffee: Patterns of consumption. Geo J. 2002, 57, 283-294.
14. Reissig, C.J.; Strain, E.C.; Griffiths, R.R. Caffeinated energy drinks-a growing problem. Drug Alcohol Depend. 2009, 99, 1-10.
15. Cornelis, M.C.; El-Sohemy, A.; Kabagambe, E.K.; Campos, H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006, 295, 1135-1141.
16. Fredholm, B.B.; Battig, K.; Holmen, J.; Nehlig, A.; Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51, 83-133.
17. Smith, A. Effects of caffeine on human behavior. Food Chem. Toxicol. 2002, 40, 1243-1255.
18. Lorist, M.M.; Snel, J.; Kok, A.; Mulder, G. Influence of caffeine on selective attention in well-rested and fatigued subjects. Psychophysiology 1994, 31, 525-534.
19. Childs, E.; de Wit, H. Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 2006, 185, 514-523.
20. James, J.E.; Rogers, P.J. Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation. Psychopharmacology (Berl) 2005, 182, 1-8.
21. Goldstein, J.; Silberstein, S.D.; Saper, J.R.; Ryan, R.E. Jr.; Lipton, R.B. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006, 46, 444-453.
22. Bigal, M.E.; Sheftell, F.D.; Rapoport, A.M.; Tepper, S.J.; Lipton, R.B. Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002, 42, 575-581.
23. Hernan, M.A.; Takkouche, B.; Caamano-Isorna, F.; Gestal-Otero, J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 2002, 52, 276-284.
24. Arendash, G.W.; Schleif, W.; Rezai-Zadeh, K.; Jackson, E.K.; Zacharia, L.C.; Cracchiolo, J.R.; Shippy, D.; Tan, J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain [β]-amyloid production. Neuroscience 2006, 142, 941-952.
25. Cannon, M.E.; Cooke, C.T.; McCarthy, J.S. Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products. Med. J. Aust. 2001, 174, 520-521.
26. De Vreede-Swagemakers, J.J.; Gorgels, A.P.; Weijenberg, M.P.; Dubois-Arbouw, W.I.; Golombeck, B.; van Ree, J.W.; Knottnerus, A.; Wellens, H.J. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. J. Clin. Epidemiol. 1999, 52, 601-607.
27. Corti, R.; Binggeli, C.; Sudano, I.; Spieker, L.; Hänseler, E.; Ruschitzka, F.; Chaplin, W.F.; Lüscher, T.F.; Noll, G. Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content: role of habitual versus nonhabitual drinking. Circulation 2002, 106, 2935-2940.
28. Arnlov, J.; Vessby, B.; Riserus, U. Coffee consumption and insulin sensitivity. JAMA 2004, 291, 1199-1201.
29. MacKenzie, T.; Comi, R.; Sluss, P.; Keisari, R.; Manwar, S.; Kim, J.; Larson, R.; Baron, J.A. Metabolic and hormonal effects of caffeine: randomized, double-blind, placebo-controlled crossover trial. Metabolism 2007, 56, 1694-1698.
30. Agardh, E.E.; Carlsson, S.; Ahlbom, A.; Efendic, S.; Grill, V.; Hammar, N.; Hilding, A.; Ostenson, C.G. Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women. J. Intern. Med. 2004, 255, 645-652.
31. Williams, C.J.; Fargnoli, J.L.; Hwang, J.J.; van Dam, R.M.; Blackburn, G.L.; Hu, F.B.; Mantzoros, CS. Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care 2008, 31, 504-507.
32. Klatsky, A.L.; Morton, C.; Udaltsova, N.; Friedman, G.D. Coffee, cirrhosis, and transaminase enzymes. Arch. Intern. Med. 2006, 166, 1190-1195.
33. Choi, H.K.; Willett, W.; Curhan, G. Coffee consumption and risk of incident gout in men: A prospective study. Arthritis Rheum. 2007, 56, 2049-2055.
34. Burke, LM. Caffeine and sports performance. Appl. Physiol. Nutr. Metab. 2008, 33, 1319.
35. Lopez-Garcia, E.; van Dam, R.M.; Li, T.Y.; Rodriguez-Artalejo, F.; Hu, FB. The relationship of coffee consumption with mortality. Ann. Intern. Med. 2008, 148, 904-914.
36. Boehm, K.; Borrelli, F.; Ernst, E.; Habacher, G.; Hung, S.K.; Milazzo, S.; Horneber, M. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst. Rev. 2009, CD005004.
37. Kanis, J.A.; Johnell, O.; Oden, A.; De Laet, C.; Jonsson, B.; Dawson, A. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002, 30, 251-258.
38. Cauley, J.A.; Hochberg, M.C.; Lui, L.Y.; Palermo, L; Ensrud, K.E.; Hillier, T.A.; Nevitt, M.C.; Cummings, S.R. Long-term risk of incident vertebral fractures. JAMA 2007, 298, 2761-2767.
39. Uhde, T.W. Caffeine provocation of panic: a focus on biological mechanisms. In Neurobiology of Panic Disorder; Ballenger, J.C., Ed.; Alan R. Liss Inc: New York, NY, USA, 1990; pp. 219-242.
40. Bruce, M.; Scott, N.; Shine, P.; Lader, M. Anxiogenic effects of caffeine in patients with anxiety disorders. Arch Gen. Psychiatry 1992, 49, 867-869.
41. Satel, S. Is caffeine addictive?--a review of the literature. Am. J. Drug Alcohol Abuse 2006, 32, 493-502.
42. Nehlig, A. Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci. Biobehav. Rev. 1999, 23, 563-576.
43. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision, 4th ed.; American Psychiatric Association: Washington, DC, USA, 2000.
44. Juliano, L.M.; Griffiths, R.R. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) 2004, 176, 1-29.
45. Schevelbein H.; Eberhardt, R.; Loeschenkohl, K.; Rahlfs, J.; Bedall, J.K. Absorption of nicotine through the oral mucosa-measurement of nicotine concentration in the blood after application of nicotine and total particulate matter. Agents Actions 1973, 3, 254-258.
46. Perez-Stable, E.J.; Herrera, B.; Jacob, P.; Benowitz, N.L. Nicotine metabolism and intake in black and white smokers. JAMA 1998, 280, 152-156.
47. Malaiyandi, V.; Sellers, E.M.; Tyndale, R.F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin. Pharmacol. Ther. 2005, 77, 145-158.
48. Saccone, N.L.; Saccone, S.F.; Hinrichs, A.L.; Stitzel, J.A.; Duan, W.; Pergadia, M.L.; Agrawal, A.; Breslau, N.; Grucza, R.A.; Hatsukami, D.; et al. Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B, 453-466.
49. Benowitz, N.L. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 597-613.
50. Benowitz, N.L.; Kuyt, F.; Jacob, P. Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. Clin. Pharmacol. Ther. 1984, 36, 74-81.
51. Okamura, T.; Noboru, T. Mechanism underlying nicotine-induced relaxation in dog saphenous arteries. Eur. J. Pharmacol. 1994, 263, 85-91.
52. Dani J.A. Roles of dopamine signaling in nicotine addiction. Mol. Psychiatry 2003, 8, 255-256.
53. Levin, E.D.; Rezvani, A.H. Nicotinic treatment for cognitive dysfunction. Curr. Drug. Targets CNS Neurol. Disord. 2002, 4, 423-431.
54. Pickering, T.; Schwartz, J.E.; James, C.T. Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Clin. Exp. Pharmacol. Physiol. 1995, 22, 226-231.
55. Kool, M.J.; Hoeks, A.P.; Struijker Boudier, J.A.; Reneman, R.S.; Van Bortel, L.M. Short and long-term effects of smoking on arterial wall properties in habitual smokers. J. Am. Coll. Cardiol. 1993, 22, 1881-1886.
56. Mikkelsen, K.L.; Wiinberg, N.; Hoegholm, A.;Christensen, H.R.; Bang, L.E.; Nielsen, P.E.; Svendsen, T.L.; Kampmann, J.P.; Madsen, N.H.; Bentzon, M.W. Smoking related to 24-h ambulatory blood pressure and heart rate. A study in 352 normotensive Danish subjects. Am J Hypertens. 1997, 10, 483-491.
57. Benowitz, N.L.; Sharp, D.S. Inverse relation between serum cotinine concentration and blood pressure in cigarette smokers. Circulation 1989, 80, 1309-1312.
58. Quillen, J.E.; Rossen, J.D.; Oskarsson, H.J.; Minor, R.L., Jr.; Lopez, A.G.; Winniford, M.D. Acute effect of cigarette smoking on the coronary circulation: Constriction of epicardial and resistance vessels. J. Am. Coll. Cardiol. 1993, 22, 6426-47.
59. Iida, M.; Iida, H.; Dohi, S.; Takenaka, M.; Fujiwara, H. Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo. Stroke 1998, 29, 1656-1665.
60. Kannel, W.B.; D'Agostino, R.B.; Belanger, A.J. Fibrinogen, cigarette smoking and the risk of cardiovascular disease from the Framingham Study. Am. Heart J. 1987, 113, 1006-1010.
61. Meade, T.W.; Imeson, J.; Stirling, Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischemic heart disease. Lancet 1987, 2, 986-988.
62. Benowitz, N.L. The role of nicotine in smoking-related cardiovascular disease. Prev. Med. 1997, 26, 412-417.
63. Zidovetzki, R.; Chen, P.; Fisher, M.; Hofman, F.M. Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway. Stroke 1999, 30, 651-655.
64. Rivers, J.T.; White, H.D.; Cross, D.B.; Williams, B.F.; Norris, R.M. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking. J. Am. Coll. Cardiol. 1990, 16, 340-348.
65. Pell, J.P. Does smoking cessation reduce the risk of restenosis following coronary angioplasty? Heart 2000, 84, 233-234.
66. Kiowski, W.; Linder, L.; Stoschitzky, K.; Pfisterer, M.; Burckhardt, D.; Burkart, F.; Bühler F.R. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994, 90, 27-34.
67. Mjos, O.D. Lipid effects of smoking. Am. Heart J. 1988, 115, 272-275.
68. Criqui, M.H.; Cowan, L.D.; Tyroler, H.A.; Bangdiwala, S.; Heiss, G.; Wallace, R.B.; Cohn, R. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: Results from the Lipid Research Clinic Follow-up Study. Am. J. Epidemiol. 1987, 126, 629-637.
69. Eliasson, B.; Taskinen, M.R.; Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation 1996, 94, 878-881.
70. Murray, R.P.; Bailey, W.C.; Daniels K.; Bjornson, W.M.; Kurnow, K.; Connett, J.E.; Nides, M.A.; Kiley, J.P. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Chest 1996, 109, 438-445.
71. Joseph, A.M.; Norman, S.M.; Ferry, L.H.; Prochazka, A.V.; Westman, E.C.; Steele, B.G.; Sherman, S.E.; Cleveland, M.; Antonuccio, D.O.; Hartman, N.; McGovern, P.G. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N. Engl. J. Med. 1996, 335, 1792-1798.
72. Kimmel, S.E.; Berlin, J.A.; Miles, C.; Jaskowiak, J.; Carson, J.L.; Strom, B.L. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J. Am. Coll. Cardiol. 2001, 37, 1297-1302.
73. Catassi, A.; Servent, D.; Paleari, L.; Cesario, A.; Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: Implications on lung carcinogenesis. Mutat. Res. 2008, 659, 221-231.
74. Dasgupta, P.; Kinkade, R.; Joshi, B.; Decook, C.; Haura, E.; Chellappan, S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and surviving. Proc. Natl. Acad. Sci. USA 2006, 103, 6332-6337.
75. Hughes, J.R.; Hatsukami, D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 1986, 43(3), 289-294.
76. Hughes, J.R. Clinical significance of tobacco withdrawal. Nicotine Tob. Res. 2006, 8, 153-156.
77. Patten, C.A.; Martin, JE. Measuring tobacco withdrawal: a review of self-report questionnaires. J. Subst. Abuse 1996, 8(1), 93-113.
78. Wilkes, S. The use of bupropion SR in cigarette smoking cessation. Int. J. Chron. Obstruct. Pulmon. Dis. 2008, 3(1), 45-53.
79. Coe, J.W.; Brooks, P.R.; Vetelino, M.G.; Wirtz, M.C.; Arnold, E.P.; Wirtz, M.C.; Arnold, E.P.; Huang, J.; Sands, S.B.; Davis, T.I.; Lebel, L.A.; Fox, CB; et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 2005, 48, 3474-3477.
80. Gonzales, D.; Rennard, S.I.; Nides, M.; Oncken, C.; Azoulay, S.; Oncken, C.; Azoulay, S.; Billing, C.B.; Watsky, E.J.; Gong, J.; Williams, K.E.; Reeves, K.R. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296, 47-55.
81. Tonstad, S.; Tonnesen, P.; Hajek, P.; Williams, K.E.; Billing, C.B.; Reeves, K.R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296, 64-71.
82. World Drug Report 2007. Report no. E.07.XI.5; United Nations Office on Drugs and Crime: Vienna, Austria, 2007; http://www.unodc.org/documents/data-and-analysis/WDR-2007.pdf, accessed on 21 July 2010.
83. Montoya, I.D.; Chilcoat, H.D. Epidemiology of coca derivatives use in the Andean region: a tale of five countries. Subst. Use Misuse 1996, 31, 1227-1240.
84. Myers, M.G.; Rohsenow, D.J.; Monti, P.M.; Dey, A. Patterns of cocaine use among individuals in substance abuse treatment. Am. J. Drug Alcohol Abuse 1995, 21, 223-231.
85. Rothman, R.B.; Baumann, M.H.; Dersch, C.M. et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39, 32-41.
86. Howell, L.L.; Kimmel, H.L. Monoamine transporters and psychostimulant addiction. Biochem. Pharmacol. 2008, 75, 196-217.
87. Dackis, C.A.; O'Brien, C.P. Cocaine dependence: a disease of the brain's reward centers. J. Subst. Abuse Treat. 2001, 21, 111-117.
88. Tisdale, J.E.; Shimoyama, H.; Sabbah, H.N.; Webb, C.R. The effect of cocaine on Ventricular fibrillation threshold in the normal canine heart. Pharmacotherapy 1996, 16, 429-437.
89. Magnano, A.R.; Talathoti, N.B.; Hallur, R.; Jurus, D.T.; Dizon, J.; Holleran, S.; Bloomfield, D.M.; Collins, E.; Garan, H. Effect of acute cocaine administration on the QTc interval of habitual users. Am. J. Cardiol. 2006, 97, 1244-1246.
90. Hatsukami, D.K.; Fischman, M.W. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA 1996, 276, 1580-1588.
91. Shesser, R.; Jotte, R.; Olshaker, J. The contribution of impurities to the acute morbidity of illegal drug use. Am. J. Emerg. Med. 1991, 9, 336-342.
92. Ostrea, E.M., Jr. Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Curr. Probl. Pediatr. 1999, 29, 37-56.
93. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001, 108, 776-789.
94. Gossop, M.; Griffiths, P.; Powis, B.; Strang, J. Cocaine: patterns of use, route of administration, and severity of dependence. Br. J. Psychiatry 1994, 164, 660-664.
95. Anthony, J.C.; Warner, L.A.; Kessler, R.C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 1994, 2, 244-268.; http://www.umbrellasociety.ca/web/files/u1/Comp_epidemiology_addiction.pdf/, accessed on 21 July 2010.
96. Results from the 2006 National Survey on Drug Use and Health, National Findings; Report no. SMA 07-4293.; Office of Applied Studies, Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2005.
97. Warner, A.; Norman, A.B. Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther. Drug Monit. 2000, 22, 266-270.
98. Pennings, E.J.; Leccese, A.P.; Wolff, F.A. Effects of concurrent use of alcohol and cocaine. Addiction 2002, 97, 773-783.
99. Angrist, B. Clinical effects of central nervous system stimulants: A selective update. In Brain Reward Systems and Abuse; Engel, J., Oreland, L., Ingvar, D.H., Eds.; Raven Press: New York, NY, USA, 1987; pp. 109-127.
100. Fischman, M.W.; Foltin, R.W. Cocaine self-administration research: implications for rational pharmacotherapy. In Behavior, Pharmacology, and Clinical Applications; Higgins, S.T., Katz, J.L., Eds.; Cocaine Abuse Academic Press: San Diego, CA, USA, 1998; pp. 181-207.
101. Williamson, S.; Gossop, M.; Powis, B.; Griffiths, P.; Fountain, J.; Strang, J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend. 1997, 44, 87-94.
102. Rosse, R.B.; Fay-McCarthy, M.; Collins, J.P., Jr.; Risher-Flowers D, Alim TN, Deutsch SI. Transient compulsive foraging behavior associated with crack cocaine use. Am. J. Psychiatry 1993, 150, 155-156.
103. Palha, A.P.; Esteves, M. Drugs of abuse and sexual functioning. Adv. Psychosom. Med. 2008, 29, 131-149.
104. Luis, A.; Tamam, M.; Deepak, T. Crack Whips the Heart: A Review of the Cardiovascular Toxicity of Cocaine. Am. J. Cardiol. 2007, 100, 1040-1043.
105. Neiman, J.; Haapaniemi, H.M.; Hillbom, M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur. J. Neurol. 2000, 7, 595-606.
106. Qureshi, A.I.; Suri, F.K.; Guterman, LR.; Hopkins, LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke. Circulation 2001, 103, 502-506.
107. Lange, R.A.; Hillis, L.D. Cardiovascular complications of cocaine use. N. Engl. J. Med. 2001, 345, 351-358.
108. Petitti, D.B.; Sidney, S.; Quesenberry, C.; Bernstein A. Stroke and cocaine or amphetamine use. Epidemiology 1998, 9, 596-600.
109. Brust, J.C. Acute neurologic complications of drug and alcohol abuse. Neurol. Clin. 1998, 16, 503-513.
110. Khantzian, E.J.; McKenna, G.J. Acute toxic and withdrawal reactions associated with drug use and abuse. Ann. Intern. Med. 1979, 90, 361-372.
111. Coffey, S.F.; Dansky, B.S.; Carrigan, M.H.; Brady, K.T. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend. 2000, 59, 277-286.
112. Nademanee, K.; Gorelick, D.A.; Josephson, M.A.; Ryan M.A.; Wilkins, J.N.; Robertson, H.A.; Mody, F.V.; Intarachot, V. Myocardial ischemia during cocaine withdrawal. Ann. Intern. Med. 1989, 111, 876-880.
113. Bertolet, B.D.; Freund, G.; Martin, C.A.; Perchalski, D.L.; Williams, C.M.; Pepine C.J. Unrecognized left ventricular dysfunction in an apparently healthy cocaine abuse population. Clin. Cardiol. 1990, 13, 323-328.
114. Norris, K.C.; Thornhill-Joynes, M.; Robinson, C.; Strickland, T.; Alperson, B.L.; Witana, S.C.; Ward, H.J. Cocaine use, hypertension, and end-stage renal disease. Am. J. Kidney Dis. 2001, 38, 523-528.
115. Boghdadi, M.S.; Henning, R.J. Cocaine: Pathophysiology and clinical toxicology. Heart Lung 1997, 26, 466-483.
116. Little, K.Y.; Ramssen, E.; Welchko, R.; Volberg, V.; Roland, C.J.; Cassin, B. Decreased brain dopamine cell numbers in human cocaine users. Psychiatry Res. 2009, 168, 173-180.
117. Rojas, R.; Riascos, R.; Vargas, D.; Cuellar, H.; Borne, J. Neuroimaging in drug and substance abuse part I: cocaine, cannabis, and ecstasy. Top Magn. Reson. Imaging 2005, 16, 231-238.
118. Rogers, R.D.; Robbins, T.W. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr. Opin. Neurobiol. 2001, 11, 250-257.
119. Lange, R.A.; Cigarroa, R.G.; Flores, E.D.; McBride, W.; Kim, A.S.; Wells, P.J.; Bedotto, J.B.; Danziger, R.S.; Hillis, L.D. Potentiation of cocaine-induced coronary vasoconstriction by β-adrenergic blockade. Ann. Intern. Med. 1990, 112, 897-903.
120. Dattilo, P.B.; Hailpern, S.M.; Fearon, K.; Sohal, D.; Nordin C. β-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann. Emerg. Med. 2008, 51(2), 117-125.
121. Boehrer, J.D.; Moliterno, D.J.; Willard, J.E.; Hillis, L.D.; Lange, R.A. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am. J. Med. 1993, 94, 608-610.
122. Schuckit, M.A. Drug and Alcohol Abuse. A Clinical Guide to Diagnosis and Treatment, 6th ed.; Springer: New York, NY, USA, 2006.
123. Carroll, K.M. Recent advances in the psychotherapy of addictive disorders. Curr. Psychiatry Rep. 2005, 7, 329-336.
124. Zhang, Z.; Friedmann, P.D.; Gerstein, D.R. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003, 98, 673-684.
125. Weiss, R.D.; Griffin, M.L.; Gallop, R.J.; Najavits, L.M; Frank, A.; Crits-Christoph, P.; Thase, M.E.; Blaine, J.; Gastfriend, D.R.; Daley, D.; et al. The effect of 12-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. Drug Alcohol Depend. 2005, 77, 177-184.
126. Kampman, K.M.; Pettinati, H.; Lynch, K.G.; Dackis, C.; Sparkman, T.; Weigley, C.; O'Brien, C.P. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004, 75, 233-240.
127. Gonzalez, G.; Desai, R.; Sofuoglu, M.; Poling, J.; Oliveto, A.; Gonsai, K.; Kosten, T.R. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007, 87, 1-9.
128. Shoptaw, S.; Yang, X.; Rotheram-Fuller, E.J.; Hsieh, Y.C.; Kintaudi, P.C.; Charuvastra, V.C.; Ling, W. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J. Clin. Psychiatry 2003, 64, 1440-1448.
129. Moeller, F.G.; Schmitz, J.M.; Steinberg, J.L.; Green, C.M.; Reist, C.; Lai, L.Y.; Swann, A.C.; Grabowski, J. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am. J. Drug Alcohol Abuse 2007, 33, 367-378.
130. Shearer, J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug Alcohol Rev. 2008, 27, 301-308.
131. Rush, C.R.; Stoops, W.W.; Hays, L.R. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend. 2009, 99, 261-271.
132. Mardikian, P.N.; LaRowe, S.D.; Hedden, S.; Kalivas, P.W.; Malcolm, R.J. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 389-394.
133. Martell, B.A.; Mitchell, E.; Poling, J. Gonsai, K.; Kosten, T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry 2005, 58, 158-164.
134. Gaval-Cruz, M.; Weinshenker, D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol. Interv. 2009, 9(4), 175-187.
135. Blaho, K.; Logan, B.; Winbery, S.; Park, L.; Schwilke, E. Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. Am. J. Emerg. Med. 2000, 18, 593-598.
136. Beebe, D.K.; Walley, E. Substance abuse: the designer drugs. Am. Fam. Physician 1991, 43, 1689-1698.
137. Peroutka, S.J. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, 'ecstasy') on an undergraduate campus. N. Engl. J. Med. 1987, 317, 1542-1543.
138. Webb, E.; Ashton, CH.; Kelly, P.; Kamali, F. Alcohol and drug use in UK university students. Lancet 1996, 348, 922-925.
139. Buchert, R.; Thomasius, R.; Nebeling, B.; Petersen, K.; Obrocki, J.; Jenicke, L.; Wilke, F.; Wartberg, L.; Zapletalova, P.; Clausen, M. Long-term effects of ecstasy use on serotonin transporters of the brain investigated by PET. J. Nucl. Med. 2003, 44, 375-384.
140. Daws, L.; Irvine, R.J.; Callaghan, P.D.; Toop, P.N.; White, J.M.; Bochner, F. Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylene-dioxymethamphetamine in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 2000, 24, 955-977.
141. Rattray, M. Ecstasy: Towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 1991, 26, 77-87.
142. Ling, L.H.; Marchant, C.; Buckley, N.A.; Prior, M.; Irvine, R.J. Poisoning with the recreational drug paramethoxyamphetamine ("death"). Med. J. Aust. 2001, 174, 453-455.
143. Liester, M.B.; Grob, C.S.; Bravo, G.L.; Walsh, R.N. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J. Nerv. Ment. Dis. 1992, 180, 345-352.
144. Zemishlany, Z.; Aizenberg, D.; Weizman A. Subjective effects of MDMA ('Ecstasy') on human sexual function. Eur. Psychiatry. 2001, 16(2), 127-130.
145. Milroy, C.M.; Clark, J.J.C.; Forrest A.R. Pathology of deaths associated with ecstasy and "eve" misuse. J. Clin. Pathol. 1996, 49, 149-153.
146. Webb, C.; Williams, V. Ecstasy intoxication: appreciation of complications and the role of dantrolene. Anaesthesia 1993, 48, 542-543.
147. Henry, J.A.; Jeffreys, K.J.; Dawling, S. Toxicity and deaths from 3,4-metylenedioxymethamphetamine ("ecstasy"). Lancet 1992, 340, 384-387.
148. Gowing, L.R.; Henry-Edwards, S.M.; Irvine, R.J.; Ali R.L. The health effects of ecstasy: a litterature review. Drug Alcohol Rev. 2002, 21, 53-63.
149. Dumont, G.J.; Kramers, C.; Sweep, F.C.; Touw, D.J.; van Hasselt, J.G.; de Kam, M.; van Gerven, JM.; Buitelaar, JK.; Verkes, RJ. Cannabis coadministration potentiates the effects of ecstasy on heart rate and temperature in humans. Clin. Pharmacol. Ther. 2009, 86(2), 160-166.
150. Lester, S.J.; Baggott, M.; Welm, S.; Schiller N.B.; Jones, R.T.; Foster, E.; Mendelson, J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann. Intern. Med. 2000, 133, 969-973.
151. Hegadoren, K.M.; Baker, G.B.; Bourin, M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci. Biobehav. Rev. 1999, 23, 539-553.
152. Curran, HV.; Travill, RA. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): week-end high followed by mid-week low. Addiction 1997, 92(7), 821-831.
153. Cohen, R.S.; Cocores, J. Neuropsychiatric manifestation following the use of 3,4-methylenedioxymethamphetamine (MDMA: ecstasy). Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21, 727-734.
154. Benazzi, F.; Mazzoli, M. Psychiatric illness associated with ecstasy. Lancet 1991, 338, 1520. 155. Pallanti, S.; Mazzi D. MDMA (ecstasy) precipitation of panic disorder. Biol. Psychiatry 1992, 32, 91-95.
155. Obrocki, J.; Buchert, R.; Vaterlein, O.; Thomasius, R.; Beyer, W.; Schiemann, T. Ecstasy-long term effects on the human central nervous system revealed by positron emission tomography. Br. J. Psychiatry 1999, 175, 186-188.
156. Kish, S.J.; Furukawa, Y.; Ang, L.; Vorce, SP.; Kalasinski, KS. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 2000, 55, 294-296.
157. Bolla, K.I.; McCann, U.D.; Ricaurte, G.A. Memory impairment in abstinent MDMA (ecstasy) users. Neurology 1998, 51, 1532-1537.
158. Wareing, M.; Fisk, J.E.; Murphy, P.N. Working memory deficits in current and previous users of MDMA ("ecstasy"). Br. J. Psychol. 2000, 91, 181-188.
159. Hall, A.P. Ecstasy and the anaesthetist. Br. J. Anaest. 1997, 79, 697-698.
160. Degenhardt, L.; Bruno, R.; Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010, 107(1), 1-10.
161. Topp, L.; Hando, J.; Dillon, P.; Roche, A.; Solowij, N. Ecstasy use in Australia: pattern of use and assiociated harms. Drug Alcohol Depend. 1999, 55, 105-115.
162. Stein, D.J.; Rink, J. Effects of ecstasy blocked by serotonin reuptake inhibitors. J. Clin.Psychiatry 1999, 60, 485.
163. Rogers, G.; Elston, J.; Garside, R.; Roome, C.; Taylor, R.; Younger, P.; Zawada, A.; Somerville, M. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol. Assess 2009, 13(6), iii-iv, ix-xii, 1-315.
164. Methamphetamine use: 2002, 2003, 2004 and 2005, NSDUH Report; Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2007; http://www.drugabusestatistics.samhsa.gov/2k7/meth/meth.pdf/, accessed on 21 July 2010.
165. Methamphetamine Use, Abuse, and Dependence: 2002, 2003, and 2004, NSDUH Report; Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2005; http://www.drugabusestatistics.samhsa.gov/2k5/meth/meth.htm/, accessed on 21 July 2010.
166. Colfax, G.; Vittinghoff, E.; Husnik, M.J.; McKirnan, D.; Buchbinder, S.; Koblin, B.; Celum, C.; Chesney, M.; Huang, Y.; Mayer, K.; et al., For the EXPLORE Study Team. Substance use and sexual risk: a participant-and episode-level analysis among a cohort of men who have sex with men. Am. J. Epidemiol. 2004, 59, 1002-1012.
167. Santos, A.P.; Wilson, A.K.; Hornung, C.A.; Polk, H.C., Jr.; Rodriguez, J.L; Franklin G.A. Methamphetamine laboratory explosions: a new and emerging burn injury. J. Burn Care Rehabil. 2005, 26, 228-232.
168. Smoked Methamphetamine/amphetamine: 1992-2002.; DASIS Report; Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2005; http://www.oas.samhsa.gov/2k4/methSmoked/methSmoked.pdf/, accessed on 21 July 2010.
169. Methamphetamine abuse. Med. Lett. Drugs Ther. 2004, 46, 62-63.
170. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; Logan, J.; Gatley, S.J.; Wong, C.; Hitzemann, R. Pappas N.R. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J. Pharmacol. Exp. Ther. 1999, 291, 409-415.
171. Shoptaw, S. Methamphetamine use in urban gay and bisexual populations. Top HIV Med. 2006, 14, 84-87.
172. McKetin, R.; Kelly E.; McLaren, J. The relationship between crystalline methamphetamine use and dependence. Drug Alcohol Depend. 2006, 58, 198-204.
173. Buchanan, J.F.; Brown, C.R. "Designer drugs". A problem in clinical toxicology. Med Toxicol Adverse Drug Exp. 1988, 3, 1-17.
174. Turnipseed, S.D.; Richards, J.R; Kirk, J.D.; Diercks, D.B.; Amsterdam, E.A. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J. Emerg. Med. 2003, 24(4), 369-373.
175. Derlet, R.W.; Rice, P.; Horowitz, B.Z.; Lord, R.V. Amphetamine toxicity: experience with 127 cases. J. Emerg. Med. 1989, 7, 157-161.
176. Kaye, S.; Darke, S.; Duflou, J.; McKetin, R. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 2008, 103(8), 1353-1360.
177. Sekine, Y.; Menibe, Y.; Ouchi, Y.; Takei, N.; Iyo, M.; Nakamura, K.; Suzuki, K.; Tsukada, H.; Okada, H.; Yoshikawa, E.; et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateralprefrontal cortices with methamphetamine-related psychiatric symptoms. Am. J. Psychiatry 2003, 160, 1699-1701.
178. Srisurapanont, M.; Jarusuraisin, N.; Kittirattanapaiboon, P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst. Rev. 2001, (4), CD003022.
179. Newton, T.F.; Roache, J.D.; De La Garza, R., 2nd.; Fong, T.; Wallace, C.L.; Li, S.H.; Elkashef, A.; Chiang, N.; Kahn, R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006, 31, 1537-1344.
180. Manghi, R.; Broers, B.; Benguettat, D.; Khazaal, Y; Khan, R; Zullino, D.F. Khat use: lifestyle or addiction? J. Psychoactive Drugs 2009, 41(1), 1-10.
181. Al-Motarreb, A.; Baker, K.; Broadley, K.J. Khat: pharmacological and medical aspects and its social use in Yemen. Phytother. Res. 2002, 16(5), 403-413.
182. Halket, J.M.; Karasu, Z.; Murray-Lyon, I.M. Plasma cathinone levels following chewing khat leaves (Catha edulis Forsk.). J. Ethnopharmacol. 1995, 49(2), 111-113.
183. Widler, P.; Mathys, K.; Brenneisen, R.; Kalix, P.; Fisch, H.U. Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin. Pharmacol. Ther. 1994, 55(5), 556-562.
184. Stefan, J.; Mathew, B. Khat chewing: an emerging drug concern in Australia? Aust N Z J Psychiatry 2005, 39(9), 842-843.
185. Bhui, K.; Abdi, A.; Abdi, M.; Pereira, S.; Dualeh, M.; Robertson, D.; Sathyamoorthy, G.; Ismail H. Traumatic events, migration characteristics and psychiatric symptoms among Somali refugees-preliminary communication. Soc. Psychiatry Psychiatr. Epidemiol. 2003, 38(1), 35-43.
186. Brenneisen, R.; Fisch, H.U.; Koelbing, U.; Geisshusler, S.; Kalix, P. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br. J. Clin. Pharmacol. 1990, 30(6), 825-828.
187. Kalix, P. Khat: A Plant with Amphetamine Effects. J. Subst. Abuse Treat. 1988, 5, 163-169.
188. Ali, A.A.; Al-Sharabi, A.K.; Aguirre, J.M.; Nahas, R. A Study of 342 oral keratotic white lesions induced by qat chewing among 2500 Yemeni. J. Oral Pathol. Med. 2004, 33(6), 368-372.
189. Eriksson, M.; Ghani, N.A.; Kristiansson, B. Khat-chewing during pregnancy-effect upon the off-spring and some characteristics of the chewers. East. Afr. Med. J. 1991, 68(2), 106-111.
190. Giannini, A.J.; Miller, N.S.; Turner, C.E. Treatment of Khat addiction. J. Subst. Abuse Treat. 1992, 9(4), 379-382.
191. Giannini, A.J; Nakoneczie, A.M. Treatment of Khat Addiction with Bromocriptine Mesylate: A Case Report and Review of Cocaine-and Amphetamine-Like Effects. Am. J. Ther. 1995, 2(7), 487-489.
192. Friedman, R.A. The changing face of teenage drug abuse-The trend toward prescription drugs. N. Engl. J. Med. 2006, 354, 1448-1450.
193. Kuehn, B.M. Prescription drug abuse rises globally. JAMA 2007, 297, 1306. 195. McCarthy, M. Prescription drug abuse up sharply in the USA. Lancet 2007, 369, 1505-1506.
194. Portenoy, R.K. Opioid therapy for chronic non-malignant pain: a review of critical issues. J. Pain Symptom. Manage. 1996, 11, 203-217.
195. DuPont, RL. The brain and prescription drug abuse. In Balancing the Response to Prescription Drug Abuse: Report of a National Symposium on Medicine and Public Policy; Wilford, B.B., Ed.; American Medical Association: Chicago, IL, USA, 1990.
196. Parran, T., Jr. Prescription drug abuse. A question of balance. Med. Clin. North Am. 1997, 81, 967-978.
197. Adler, L.A.; Goodman, D.W.; Kollins, S.H.; Weisler, R.H.; Krishnan, S.; Zhang, Y.; Biederman, J. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2008, 69, 1364-1373.
198. Mitler, M.M.; Hajdukovic, R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991, 14, 218-220.
199. Van Geffen, E.C.; Hugtenburg, J.G.; Heerdink, E.R.; van Hulten, R.P.; Egberts, A.C. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur. J. Clin. Pharmacol. 2005, 61, 303-307.
200. Compton, W.M.; Volkow, N.D. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006, 83 (Suppl. 1), S4-S7.